Inhibition of Radiographic Progression

CIMZIA provided sustained inhibition of structural joint damage.¹

RAPID 1: Inhibition of the progression of structural joint damage

In RAPID 1, CIMZIA plus methotrexate (MTX) significantly inhibited progression of structural joint damage (expressed as the mean change in modified total Sharp score [mTSS]) compared with placebo plus MTX.¹

Mean change in mTSS score at 52 weeks was 0.4 in the CIMZIA 200 mg every 2 week group, compared with 2.8 for placebo (P<.001 by rank analysis)¹
CIMZIA produced significantly greater inhibition of the progression of both erosion and joint space narrowing, which was observed at both 24 and 52 weeks¹
Similar results were seen in RAPID 2²

Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers, including children, adolescents, and young adults. Acute and chronic cases of leukemia have also been reported.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.

NEXT: Rapid Reduction of Swollen and Tender Joints »

Indication
CIMZIA is indicated for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-pay Savings Card program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-pay Savings Card program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

For more information 1-866-4-CIMZIA (1-866-424-6942)

References:

Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-3329.
Smolen JS, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
Data on file. UCB, Inc.; Smyrna, GA.

Pain, Fatigue, Disability, and Quality of Life

PEGylated Design

Mechanism of Action

Dosing and Administration

Safety Information

HCP Resources

For U.S. Healthcare Professionals

CIMZIA^®, CIMplicity™ are trademarks of the UCB Group of Companies.
OXO, Good Grips, and the associated logos are trademarks of Helen of Troy Limited and are used under license.

Inhibition of Radiographic Progression

RAPID 1: Inhibition of the progression of structural joint damage

SITEMAP

Home

Rapid Response Data

Patient-Reported Outcomes

PEGylated Design

Dosing and Administration

Safety Information